A Phase 2 clinical trial in Spinal-muscular-atrophy patients.
Latest Information Update: 20 Jan 2025
Price :
$35 *
At a glance
- Drugs Apitegromab (Primary)
- Indications Spinal muscular atrophy
- Focus Therapeutic Use
- Acronyms OPAL
- 20 Jan 2025 New trial record
- 08 Jan 2025 According to a Scholar Rock media release, the company plans Initiate this study in mid-2025.